Vitamin D and colorectal, breast, and prostate cancers: A review of the epidemiological evidence

Journal of Cancer

Volumn 7, Issue 3, 2016, Pages 232-240

  Jacobs, Elizabeth T ^a,b   Kohler, Lindsay N ^a,b   Kunihiro, Andrew G ^a,b   Jurutka, Peter W ^c,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

25(OH)D; Breast cancer; Colorectal cancer; Prostate cancer; Vitamin D

Indexed keywords

CALCIFEDIOL; COLECALCIFEROL; VITAMIN D;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

EID: 84973278430     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13403     Document Type: Review

References (118)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: Cancer J Clin 2015; 65(1):5-29.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin 2014; 64:9-29.
3. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma-carcinoma sequence. Br J Surg 2002;89:845-65.
4. Heitman SJ, Ronksley PE, Hilsden RJ, et al. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol H 2009;7:1272-8.
5. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA: Cancer J Clin 2006;56:143-596.
6. Yin L, Grandi N, Raum E, et al. Meta-analysis: Serum vitamin D and colorectal adenoma risk. Prev Med 2011;53(1-2):10-6.
7. Wei MY, Garland CF, Gorham ED, et al. Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2008;17:2958-69.
8. Jacobs ET, Hibler EA, Lance P, et al. Association between circulating concentrations of 25(OH)D and colorectal adenoma: a pooled analysis. Int J Cancer 2013;133:2980-8.
9. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011 Oct 18;8(12):686-700.
10. Horváth HC, Lakatos P, Kósa JP, et al. The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 2010;58:277-85.
11. Matusiak D, Benya RV. CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J Histochem Cytochem 2007;55:1257-64.
12. Barry EL, Rees JR, Peacock JL, et al. Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. J Clin Endocrinol Metab 2014 Oct; 99(10):E2133-7.
13. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011 Oct 1;29(28):3775-82.
14. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011;128:1414-24
15. Touvier M, Chan DS, Lau R, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1003-16.
16. Lee JE, Li H, Chan AT, et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res 2011;4:735-43.
17. Tangrea J, Helzlsouer K, Pietinen P, et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 1997;8:615-25.
18. Otani T, Iwasaki M, Sasazuki S, et al. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J Cancer 2007;97:446-51.19.
19. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 2010 Jan 21;340:b5500.20.
20. Weinstein SJ, Purdue MP, Smith-Warner SA, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2015 Mar 15;136(6):E654-64.
21. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-8
22. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. New Engl J Med 2006;354:684-96.
23. Weinstein SJ, Yu K, Horst RL, et al. Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J Epidemiol 2011;173:499-508.
24. Wong YY, Hyde Z, McCaul KA, et al. In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer. PloS One 2014;9:e99954.
25. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community:7 randomised double blind controlled trial. BMJ 2003 Mar 1;326(7387):469.
26. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-91.
27. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33:159-71.
28. Mezawa H, Sugiura T, Watanabe M, et al. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc analysis of a prospective cohort study. BMC Cancer 2010;10:347.
29. Ng K, Sargent DJ, Goldberg RM, et al. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol 2011;29:1599-606.
30. Freedman DM, Looker AC, Abnet CC, et al. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res 2010;70:8587-9731.
31. Fedirko V, Riboli E, Tjønneland A, et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomarkers Prev 2012;21:582-93.
32. Tretli S, Schwartz GG, Torjesen PA, et al. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control 2012;23:363-70.
33. Zgaga L, Theodoratou E, Farrington SM, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol 2014;32:2430-9.
34. Wesa KM, Segal NH, Cronin AM, et al. Serum 25-Hydroxy Vitamin D and Survival in Advanced Colorectal Cancer: A Retrospective Analysis. Nut Cancer 2015:1-7.
35. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol 2008;26:2984-91.
36. Maalmi H, Ordonez-Mena JM, Schottker B, et al. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur J Cancer 2014;50:1510-21.
37. Wang B, Jing Z, Li C, et al. Blood 25-hydroxyvitamin D levels and overall mortality in patients with colorectal cancer: a dose-response meta-analysis. Eur J Cancer 2014;50:2173-5.
38. Li M, Chen P, Li J, et al. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:2327-36.
39. Rohan TE, Negassa A, Chlebowski RT, et al. A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat 2009;116:339-50.
40. Yin L, Grandi N, Raum E, et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010;46:2196-205.
41. Chen P, Li M, Gu X, et al. Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies. PloS One 2013;8:e49312.
42. Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer 2014;110:2772-84.
43. Jacobs ET, Thomson CA, Flatt SW, et al. Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. Am J Clin Nutr 2011;93:108-17.
44. Engel P, Fagherazzi G, Boutten A, et al. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2010;19:2341-50.
45. Eliassen AH, Spiegelman D, Hollis BW, et al. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res 2011;13:R50.
46. Yao S, Sucheston LE, Millen AE, et al. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PloS One 2011;6:e17251.
47. Neuhouser ML, Manson JE, Millen A, et al. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol 2012;175:673-84.
48. Amir E, Cecchini RS, Ganz PA, et al. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat 2012;133:1077-88.
49. Peppone LJ, Rickles AS, Janelsins MC, et al. The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol 2012;19:2590-9.
50. Bilinski K, Boyages J. Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case-control study. Breast Cancer Res Treat 2013;137:599-607.
51. Kühn T, Kaaks R, Becker S, et al. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int J Cancer 2013;133:1689-700.
52. Mohr SB, Gorham ED, Alcaraz JE, et al. Serum 25-hydroxyvitamin D and breast cancer in the military: a case-control study utilizing pre-diagnostic serum. Cancer Causes Control 2013;24:495-504.
53. Ordóñez-Mena JM, Schöttker B, Haug U, et al. Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev 2013;22:905-16.
54. Yousef FM, Jacobs ET, Kang PT, et al. Vitamin D status and breast cancer in Saudi Arabian women: case-control study. Am J Clin Nutr 2013;98:105-10.
55. Skaaby T, Husemoen LL, Thuesen BH, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014;23:1220-9.
56. Wang J, Eliassen AH, Spiegelman D, et al. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II. Cancer Causes Control 2014;25:819-27.
57. Scarmo S, Afanasyeva Y, Lenner P, et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study. Breast Cancer Res 2013;15:R15.
58. Chlebowski RT. Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Res 2011;13:217.
59. Jacobs ET, Martinez ME, Jurutka PW. Vitamin D: marker or mechanism of action? Cancer Epidemiol Biomarkers Prev 2011; 20:585-90.
60. Chlebowski RT. Vitamin D and breast cancer incidence and outcome. Anticancer Agents Med Chem 2013;13:98-106.
61. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008;100:1581-91.
62. Vrieling A, Seibold P, Johnson TS, et al. Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors? Int J Cancer 2014;134:2972-83.
63. Palmieri C, MacGregor T, Girgis S, et al. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Path 2006;59:1334-6.
64. Goodwin PJ, Ennis M, Pritchard KI, et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009;27:3757-63.
65. Vrieling A, Hein R, Abbas S, et al. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 2011;13:R74.
66. Hatse S, Lambrechts D, Verstuyf A, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 2012;33:1319-26.
67. Zeichner SB, Koru-Sengul T, Shah N, et al. Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clinical Breast Cancer 2015 Feb;15(1):e1-11.
68. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002;76:187-92.
69. Hanley DA, Davison KS. Vitamin D insufficiency in North America. J Nutr 2005;135:332-7.
70. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10:1307-11.
71. Gee J, Bailey H, Kim K, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1alpha-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade PIN. Prostate 2013;73:970-8.
72. Braun MM, Helzlsouer KJ, Hollis BW, et al. Prostate Cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995;6:235-9.
73. Gann PH, Ma J, Hennekens CH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiology Biomarkers Prev 1996;5:121-6.
74. Nomura AM, Stemmermann GN, Lee J, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425-32.
75. Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-52.
76. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104-8.
77. Jacobs ET, Giuliano AR, Martinez ME, et al. Plasma levels of 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D and the risk of prostate cancer. J Ster Biochem Mol Biol 2004;89-90:533-7.
78. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1, 25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65.
79. Baron JA, Beach M, Wallace K, et al. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 2005;14:586-9.
80. Tuohimaa P, Tenkanen L, Syvälä H, et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:302-7.
81. Faupel-Badger JM, Diaw L, Albanes D, et al. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 2007;16:2784-6.
82. Li H, Stampfer MJ, Hollis JB, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine 2007;4:e103.
83. Mikhak B, Hunter DJ, Spiegelman D, et al. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D, and prostate cancer risk. The Prostate 2007;67:911-23.
84. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008;100:796-80481.
85. Travis RC, Crowe FL, Allen NE, et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 2009;169:1223-32.
86. Park SY, Cooney RV, Wilkens LR, et al. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer 2010;46:932-6.
87. Barnett CM, Nielson CM, Shannon J, et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 2010;21:1297-303.
88. Albanes D, Mondul AM, Yu K, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev 2011;20:1850-60.
89. Gilbert R, Metcalfe C, Fraser WD, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 2012;131:1187-96.
90. Brandstedt J, Almquist M, Manjer J, et al. Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 2012;23:1377-85.
91. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 2012;104:690-9.
92. Meyer HE, Robsahm TE, Bjorge T, et al. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr 2013;97:147-54.
93. Kristal AR, Till C, Song X, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1494-504.
94. Schenk JM, Till CA, Tangen CM, et al. Serum 25-hydroxyvitamin d concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1484-93.
95. Shui IM, Mondul AM, Lindström S, et al. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015 Mar 2; [Epub ahead of print].
96. Xu Y, Shao X, Yao Y, et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol 2014;140:1465-77.
97. Schwartz GG. Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1447-9.
98. Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab 2012;97:2315-24.
99. Fang F, Kasperzyk JL, Shui I, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PloS One 2011;6:e18625.
100. Tretli S, Hernes E, Berg JP, et al. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009;100:450-4.
101. Freedman DM, Looker AC, Chang SC, et al. Prospective study of serum vitamin D and cancer mortality in the United States. Journal of the National Cancer Institute 2007;99:1594-602.
102. Holt SK, Kolb S, Fu R, et al. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol 2013;37:666-70.
103. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006;25:127-41.
104. Peehl DM, Skowronski RJ, Leung GK, et al. Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10.
105. Frampton RJ, Omond SA, Eisman JA. Inhibition of human cancer cell growth by 1, 25-dihydroxyvitamin D3 metabolites. Cancer Res 1983;43:4443-7.
106. Giuliano AR, Franceschi RT, Wood RJ. Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. Arch Biochem Biophys 1991;285:261-9.
107. Shabahang M, Buras RR, Davoodi F, et al. 1, 25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993;53:3712-8.
108. Hollis BW. Assessment of circulating 25(OH)D and 1, 25(OH)2D: emergence as clinically important diagnostic tools. Nutr Rev 2007;65:S87-90.
109. Bea JW, Jurutka PW, Hibler EA, et al. Concentrations of the vitamin D metabolite 1, 25(OH)2D and odds of metabolic syndrome and its components. Metabolism 2015;64:447-59.
110. Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342-57.
111. Cross HS, Bareis P, Hofer H, et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001;66:287-92.
112. Bises G, Kállay E, Weiland T, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem 2004;52:985-9.
113. Jacobs ET, Van Pelt C, Forster RE, et al. CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Cancer Res 2013; 73:2563-73.
114. Lin PH, Aronson W, Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med 2015;13:3.
115. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterol 2015;148:1244-60 e16.
116. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Investigation 2008;118:3820-8.
117. Jacobs ET, Jurutka PW, Martinez ME, Alberts DS. Vitamin D, calcium, and colorectal neoplasia: new insights on mechanisms of action. Cancer Prev Res 2009;2:197-9.
118. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014;2:76-89.